期刊文献+

短肽修饰的甲氨蝶呤的制备及细胞毒性作用 被引量:3

Preparation of methotrexate modified by small peptide and study on its cytotoxic effect
原文传递
导出
摘要 目的:制备促黄体激素释放激素-甲氨蝶呤(LH-RH-MTX)并考察其对表达有促黄体激素释放激素(LH-RH)受体的肿瘤细胞的毒性作用。方法:以临床抗恶性肿瘤药物甲氨蝶呤(MTX)为模型药物,以促黄体激素释放激素[D-Lys6]LH-RH为导向物,通过共价键连接制备LH-RH-MTX。应用MTT法分别考察游离MTX和LH-RH-MTX对鼻咽癌HNE-1及前列腺癌PC-3细胞株的细胞毒性作用。结果:MTT法结果表明游离MTX和LH-RH-MTX对2种细胞株均有生长抑制作用,对前列腺癌PC-3细胞的抑制率大于鼻咽癌HNE-1细胞;给药12h后抑制率达到最大;当药物质量浓度为200.0μg.L-1,作用12h后:LH-RH-MTX对前列腺癌PC-3细胞的抑制率可高达97.73%,游离MTX为49.90%;LH-RH-MTX对鼻咽癌HNE-1细胞的抑制率为38.92%,游离MTX为7.41%;在同一种细胞株上,LH-RH-MTX的IC50值小于游离MTX。结论:经过短肽修饰的化合物LH-RH-MTX可与表达有LH-RH受体的肿瘤细胞特异性结合并发挥抑制作用,抗肿瘤活性高于游离MTX。提示用LH-RH作为TDDS的导向物,实现药物的靶向释放,提高药物生物利用度是可行的。 OBJECtIVE To prepare LH-RH - MTX and investigate its cytotoxic effect on cells with LH-RH receptors.METHODS MTX as the model drug and [D-Lys^6] LH-RH as the carrier were selected to prepare LH-RH - MTX. MTT assay was applied to examine the cytotoxic effects of LH-RH - MTX and free MTX on the nasopharyngeal carcinoma HNE-1 cell line and the prostatic carcinoma PC-3 cell line. RESULTS The results showed that free MTX and LH-RH - MTX could both inhibit the growth of the two cell lines. The inhibitory ratio on prostatic carcinoma PC-3 cells was higher than that on nasopha- ryngeal carcinoma HNE-1 cells. The inhibitory ratio was the highest after administration for 12 h. At the concentration of 200 μg·L^-1 after administration for 12 h,the ratio of LH-RH - MTX on prostatic carcinoma PC-3 cells was up to 97. 73% and that of free MTX was 49. 90%; on nasopharyngeal carcinoma HNE-1 cells, the inhibitory ratios were 38. 92% and 7. 41 %, respec tively. To the same cell line,the IC50 of LH-RH - MTX was less than that of free MTX. CONCLUSION The compound LH- RH - MTX modified by small peptide can incorporate specifically with the tumor cells with LH-RH receptors and its anti-tumor activity is higher than that of free MTX. The present study indicates that it is feasible to select LH-RH as the carrier of TDDS to deliver drugs targetedly and increase their bioavailability.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2011年第1期32-35,共4页 Chinese Journal of Hospital Pharmacy
基金 重庆市渝中区科技计划项目(编号:20100205)
关键词 促黄体激素释放激素(LH—RH) 甲氨蝶呤 靶向药物递送系统 人鼻咽癌HNE-1细胞株 人前列腺癌PC-3细胞株 luteinizing hormone-releasing hormone methotrexate LH-RH MTX targeting drug delivery system human nasopharyngeal carcinoma HNE-1 cell line human prostatic carcinoma PC-3 cell line
  • 相关文献

参考文献4

二级参考文献36

  • 1向梅,向钧,马燕,马晓艳,朱平,王占东.LHRH-PE40与宫颈癌组织结合特性的研究[J].中国生物制品学杂志,2006,19(2):169-170. 被引量:4
  • 2吴广谋,张国利,岳玉环,何畅,孟锐奇,李俊植,朱平.LHRH-PE40的免疫原性及其抗体对细胞毒作用的影响[J].中国生物制品学杂志,2006,19(3):252-254. 被引量:3
  • 3向梅,向钧,崔满华,殷艳玲,朱平.LHRH-PE40与癌细胞表面LHRH受体结合特性的检测[J].中国生物制品学杂志,2006,19(3):285-287. 被引量:4
  • 4Holland JF,Bast RC,Morton DL,et al.led.Cancer medicine.4th ed.Vol 1.Baltimore:Williams and Wilkins,1997.1067-1086.
  • 5Emens G,Ortmann O,Schulz KP,et al.LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer.Trends Endocrinol,2000,142(6):665-670.
  • 6Miller WR,Scott WN,Morris R,et al.Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist.Nature,1985,31 (3):231-233.
  • 7Eidne KA,Flanagan CA,Millar RP.Gonadotropin-releasing hormone binding sites in human breast carcinoma.Science,1985,229(4717):989-991.
  • 8Fekete M,Wittliff JL,Schally AV.Characteristics and distribution of receptors for[ D-Trp6 ] -luteinizing hormone-releasing hormone,somatostatin,epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer.J Clin Lab Anal,1989,3(3):137-147.
  • 9Baumann KH,Kierel L,Kaufmann M,et al.Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters.Breast Cancer Res Treat,1993,25 (1):37-46.
  • 10Emons G,Pahwa GS,Brack C,et al.Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata.Eur J Cancer Oncol,1989,25 (2):215-221.

共引文献6

同被引文献30

  • 1祁志荣,李虹.PE类重组免疫毒素的研究进展[J].微生物学免疫学进展,2006,34(1):50-53. 被引量:7
  • 2Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease[J]. Nature Medicine, 1995, 1(1): 27-30.
  • 3Porkka K, Laakkonen P, Hoffman J A, et al. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo[J]. Proceedings of the National Academy of Sciences, 2002, 99 (11): 7444-7449.
  • 4Grinstein E, Shan Y, Karawajew L, et al. Cell cycle-controlled interaction of nucleolin with the retinoblastoma protein and cancerous cell transformation[J]. Journal of Biological Chemistry, 2006, 281(31): 22223-22235.
  • 5Yates S P, Merrill A R. A catalytic loop within pseudomonas aeruginosa exotoxin A modulates its transferase activity[J]. Journal of Biological Chemistry, 2001, 276 (37): 35029-35036.
  • 6Yates S A S P, Merrill A R. Insight into the catalytic mechanism of pseudomonas aeruginosa exotoxin A[J]. Biochemistry, 2002, 277(48): 46669-46675.
  • 7张艳,刘秀群.高效低毒的系列功能蛋白:中国,200410033621.6[P].2004-10-03.
  • 8Taupiac M P, B6bien M, Alami M, et al. A deletion within the translocation domain of pseudomonas exotoxin A enhances translocation efficiency and cytotoxicity concomitantly [J]. Molecular Microbiology, 1999, 31(5): 1385-93.
  • 9Fitzgerald D J. Pastan I H. Recombinant pseudomonas exotoxin with increased activity: US, 5821238 A[P]. 1998-10-13.
  • 10Thundimadathil J. Cancer treatment using peptides: Current therapies and future prospects [J]. Journal of Amino Acids, 2012, 2012: doi: 10.1155120121967347.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部